Levetiracetam in epilepsy and autism spectrum disorder: analysis of safety, tolerability, and efficacy
This study supports the use of LEV for people with autism and epilepsy as there is no difference in response noted to those without autism. However, they may have less prominent changes in efficacy.
Authors
- Mary Parrett
- Sarah Pashley
- Lance Watkins (ORCID: https://orcid.org/0000-0002-0447-5906)
- William Henley (ORCID: https://orcid.org/0000-0001-6273-2619)
- Brendan McLean (ORCID: https://orcid.org/0000-0003-1419-8540)
- Sanjeev Rajakulendran (ORCID: https://orcid.org/0000-0001-9286-7696)
- Rohit Shankar (ORCID: https://orcid.org/0000-0002-1183-6933)
- Juliet Bransgrove
- Rajiv Mohanraj
- Jon Allard
- Phil Tittensor
- Melissa Maguire
- Arjune Sen
- Many Bagary
- Shan Ellawela
- Sunil Ram
Institutions
- Swansea Bay University Health Board (GB)
- University College London Hospitals NHS Foundation Trust (GB)
- University of Exeter (GB)
- Leeds Teaching Hospitals NHS Trust (GB)
- Royal Cornwall Hospital Trust (GB)
- Salford Royal NHS Foundation Trust (GB)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Birmingham and Solihull Mental Health NHS Foundation Trust (GB)
- Nottinghamshire Healthcare NHS Foundation Trust (GB)
- Norfolk Community Health and Care NHS Trust (GB)
- Oxford University Hospitals NHS Trust (GB)
- Cornwall Partnership NHS Foundation Trust (GB)
- Somerset Partnership NHS Foundation Trust (GB)
- The Royal Wolverhampton NHS Trust (GB)
- Somerset NHS Foundation Trust
Publication Details
- Journal
- Epilepsy & Behavior
- Published
- 2025-08-28
- DOI
- https://doi.org/10.1016/j.yebeh.2025.110678
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute on Handicapped Research
- Autistica
- National Institute for Health and Care Research
- National Institutes of Health